In the past week, EBS stock has gone up by 102.60%, with a monthly gain of 71.37% and a quarterly surge of 140.12%. The volatility ratio for the week is 21.66%, and the volatility levels for the last 30 days are 11.30% for Emergent Biosolutions Inc The simple moving average for the past 20 days is 82.50% for EBS’s stock, with a 28.20% simple moving average for the past 200 days.
Is It Worth Investing in Emergent Biosolutions Inc (NYSE: EBS) Right Now?
EBS has 36-month beta value of 1.17. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for EBS is 50.47M, and currently, short sellers hold a 11.68% ratio of that float. The average trading volume of EBS on May 06, 2024 was 5.49M shares.
EBS) stock’s latest price update
Emergent Biosolutions Inc (NYSE: EBS)’s stock price has increased by 17.88 compared to its previous closing price of 3.30. However, the company has seen a 102.60% increase in its stock price over the last five trading sessions. InvestorPlace reported 2024-05-02 that Emergent BioSolutions (NYSE: EBS ) layoffs are in the news as the life sciences company prepares to cut jobs and close down certain facilities. According to a release from Emergent BioSolutions, these layoffs will affect 300 of its employees.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with The Benchmark Company repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to The Benchmark Company is $5 based on the research report published on March 07, 2024 of the current year 2024.
EBS Trading at 58.10% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.25% of loss for the given period.
Volatility was left at 11.30%, however, over the last 30 days, the volatility rate increased by 21.66%, as shares surge +69.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.93% upper at present.
During the last 5 trading sessions, EBS rose by +102.60%, which changed the moving average for the period of 200-days by -45.75% in comparison to the 20-day moving average, which settled at $2.21. In addition, Emergent Biosolutions Inc saw 62.08% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from Zoon Kathryn C, who sale 1,830 shares at the price of $8.35 back on Jun 02 ’23. After this action, Zoon Kathryn C now owns 49,971 shares of Emergent Biosolutions Inc, valued at $15,280 using the latest closing price.
Zoon Kathryn C, the Director of Emergent Biosolutions Inc, sale 1,700 shares at $8.38 during a trade that took place back on May 25 ’23, which means that Zoon Kathryn C is holding 51,801 shares at $14,246 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.45 for the present operating margin
- 0.38 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.48. The total capital return value is set at -0.46. Equity return is now at value -60.56, with -23.78 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.09. The debt to equity ratio resting at 1.37. The interest coverage ratio of the stock is -7.62.
Currently, EBITDA for the company is -42.9 million with net debt to EBITDA at 9.44. When we switch over and look at the enterprise to sales, we see a ratio of 0.88. The receivables turnover for the company is 5.08for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
To put it simply, Emergent Biosolutions Inc (EBS) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
